News, reviews and podcasts from annual scientific meetings and symposiums around the world.
A drug combination targeting multiple mutant versions of cancer’s ‘death star’ protein has shown promise…
In patients with stage II colon cancer where cancer DNA was not present in the…
Results of a Phase II clinical trial led by Cedars-Sinai Cancer investigators indicate that an immunotherapy drug…
Two targeted therapies, dabrafenib (taflinar) plus trametinib (mekinst), significantly increased the overall response rate compared to…
Based on guidance from biomarker screening, patients who are 55 years of age and older…
Immunotherapy has had limited success so far against glioblastoma, the most common and aggressive form…
Recent research led by MD Anderson identified associations between neoadjuvant immune checkpoint blockade responses and B…
Use of high-dose ifosfamide (Ifex) was found to be superior for treating recurrent and primary refractory…
The use of trastuzumab deruxtecan (Enhertu), a new HER2-targeting antibody-drug conjugate, doubled progression-free survival compared…
The use of panitumumab (Vectibix) plus mFOLFOX6 significantly improved overall survival in patients with RAS wild-type metastatic…